PIK3CD and lymphoma: Particular progress has been made in studying the pan-PI3K and isoform-selective PI3K inhibitors in patients with advanced leukemias and lymphomas, including recent FDA approval of the PI3K p110δ isoform-selective inhibitor idelalisib for indolent NHL (39, 71).